Several clinical trials of recombinant IFN-α with an anti-cancer agent have been conducted for mesothelioma [9–11], but possible combinatory effects with IFN-β and CDDP or PEM was not yet demonstrated in any of previous preclinical studies. This evidence concerns the gene IFNA2 and mesothelioma.